anti-PD-L1/anti-TGF-beta bifunctional fusion protein TQB2858

{
  "id": "MLC-T-ONC-011019",
  "term": "anti-PD-L1/anti-TGF-beta bifunctional fusion protein TQB2858",
  "field": "Oncology and biomedicine",
  "definition": "A bifunctional fusion protein directed against both human programmed death ligand 1 (PD-L1) and transforming growth factor beta (TGF-beta), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, anti-PD-L1/anti-TGF-beta bifunctional fusion protein TQB2858 targets, binds to and neutralizes TGF-beta on tumor cells and simultaneously targets, binds to, and inhibits the activity of PD-L1 on the tumor cells. This prevents both TGF-beta- and PD-L1-mediated immunosuppressive pathways signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This also restores and enhances anti-tumor responses and inhibits tumor cell proliferation in susceptible tumor cells. TGF-beta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.",
  "synonyms": [
    "anti-PD-L1/TGF-beta bifunctional fusion protein TQB2858"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-pd-l1-anti-tgf-beta-bifunctional-fusion-protein-tqb2858/"
}